Cell Biotech ‘World-Class Product of Korea 2024’ Award
PR
NEWS ROOM
Cell Biotech Invites Global Pharmaceutical Companies to Visit ‘Korean Probiotics’ Production Facility
DUOLAC Opens Premium Pop-up Lounge at ‘Banyan Tree Club & Spa Seoul’
Cell Biotech Joins Asia's Largest ‘Vitafood Asia 2024’... Accelerate Exports to Asia
Cell Biotech accelerates expansion into global markets with ‘OK Kosher’ certification
Launch of new product ‘Duolac The First Class’ with 99% purity and 100 billion live Probiotics
Cell Biotech's 'Lactoclear', Selected as a National Project by the Ministry of Health and Welfare
Cell Biotech's 'DUOLAC' Secures Full Entry into All 14 Costco Stores in Taiwan
Cell Biotech's 'DUOLAC' Achieves Export Leader Status for 11 Consecutive Years
First Colorectal Cancer Drug Made from Probiotics: A 'First-in-Class' Breakthrough from Korea?
Cell Biotech to Develop 'K-Kimchi Probiotics' as Colorectal Cancer Treatment; Phase 1 Clinical Trials Planned for This Year
Cell Biotech launches 'DUOLAB Synergy Beauty Pack'—Boosting Intestinal Absorption by 149%
Highlights of Cell Biotech at Vitafoods 2024 in Geneva, Switzerland
Cell Biotech receives approval for phase 1 clinical trial of microbiome colorectal cancer new drug 'PP-P8'
Portfolio of Probiotic Ingredients from Cell Biotech Co. Ltd. achieves GRAS “No Objection” from U.S. FDA
Probiotic brand Duolac makes foray into pet market
Probiotic R&D opportunities: Duolac singles out infant, ageing, oral, liver health potential
Cell Biotech acquire a European patent for anticancer protein P8 originated from Lactobacillus rhamnosus